Latest news

• Contacts to banks for assisting Serodus in selling Serodus AS, the pipeline or the individual assets was initiated.
• Database for SER150 CL-009 is expected to be unblinded late August or early September.

Read more here

Download the minutes here

Read more here

Serodus ASA – Publishes 2023 Annual Report

Download it here

• As a consequence of Board decision in December 2023, screening of new patients is stopped.
• The last patient last visit will be August 2024.
• Report expected to be finalized in October /November 2024.
• The pipeline is being offered for sale.
• A Subsequent Offering generated NOK 4.6 million in cash.

Read more here

• After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down.
• Recruitment of patients in Australia remains very slow.
• Private Placement of 1,3 mil B-shares was completed and the proceeds of app. NOK 17 received. It was furthermore decided to do a Subsequent Offering of B-shares in early 2024.

Read more here

• Screening of patients in New Zealand improved after visiting the clinical centres involved in SER150 CL-009 study.
• The broaden of inclusion criteria for recruitment of patients to the
  SER150 CL-009 study is about to be approved by both health
  authorities and the individual clinical centres.
• The company raised app. NOK 17 M in a Private Placement.

Read more here

Download the notice here

• Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study.
• To facilitate enrolment, the entrance criteria will be revised for the SER150 CL-009 study based on feedback from investigators and serial blood collections will be removed from the protocol. 
• The company has initiated a share issue through a private placement to raise funds to finalize the SER150 Cl-009 clinical study.

Read more here

Address:
Stokholmsgade 41
2100 Copenhagen E

June 21, 2023, at 15:00

Please reserve the date